Quantcast
Home > Quotes > CTRV

ContraVir Pharmaceuticals Inc. Common Stock (CTRV) Quote & Summary Data

CTRV 
$0.4239
*  
0.0067
1.56%
Get CTRV Alerts
*Delayed - data as of Dec. 13, 2018  -  Find a broker to begin trading CTRV now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    CTRV Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
2
Today's High / Low
$ 0.435 / $ 0.38
Share Volume
759,658
50 Day Avg. Daily Volume
250,745
Previous Close
$ 0.4306
52 Week High / Low
$ 3.12 / $ 0.3701
Market Cap
6,928,188
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.37

Intraday Chart

Shares Traded

Share Volume:
759,658
50 Day Avg. Daily Volume:
250,745

Trading Range

The current last sale of $0.4239 is 14.54% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 0.435 $ 3.12
 Low: $ 0.38 $ 0.3701

Company Description (as filed with the SEC)

On December 14, 2017, the Company's Board of Directors approved a change in our fiscal year end from June 30 to December 31, effective December 31, 2017. The transition period for this Transition Report on Form 10-K is for the six months ended December 31, 2017 (which we sometimes refer to in the Transition Report as the "transition period"). In this Transition Report, our fiscal years are identified according to the calendar year in which they historically ended (e.g., the fiscal years ended June 30, 2017 is referred to as "fiscal 2017" and June 30, 2016 is referred to as "fiscal 2016" as if we had not changed our fiscal year to a calendar year on December 14, 2017 (effective December 31, 2017)). Overview We are a biopharmaceutical company (incorporated in Delaware, May 15, 2013) focused on the development of antiviral drugs with a primary emphasis on the treatment of Hepatitis B virus ("HBV") infection.  ... More ...  


Risk Grade

Where does CTRV fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 0.4302
Open Date:
Dec. 13, 2018
Close Price:
$ 0.4215
Close Date:
Dec. 13, 2018

Consensus Recommendation

Analyst Info